Investigator-assessed anti-tumor efficacy (patients with PDGFRA D842V-mutant gastrointestinal stromal tumors and patients who received avapritinib 300 mg as fourth- or later-line therapy). This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.